Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Ofole Mgbako

HIV/AIDS Medicine · NYU Langone

View

Dr. Joshua Barocas

HIV/AIDS Medicine · CU Anschutz Medical Campus

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.

    Sep 2, 2026DOI: 10.1093/cid/ciag171Journal ArticleCID

    Written by: Raphael J LandovitzYvett PinedoFederico HinestrosaGordon E CrofootCynthia BrinsonSusan BuchbinderJean-Michel MolinaRonnie M GravettJames B BrockMoti N RamgopalA Lina RosengrenIgho OfotokunJose Valdez MadrugaGeoffroy LiegeonRavindre PanchiaKhuanchai SupparatpinyoAnchalee AvihingsanonCatherine CreticosShobha SwaminathanSusanne Doblecki-LewisJorge RodriguezMarc SiegelShinichi OkaThanyawee PuthanakitBeatriz GrinsztejnEduard J SandersJavier R LamaJohannes LombaardNkosiphile NdlovuPeggy HwangJiejun DuBeth JacksonBrenda HomonyBarbara EvansPeter SklarMichael N RobertsonRebeca M Plank

    Find these authors on Roon

    RL
    Dr. Raphael J. Landovitz
    HIV/AIDS Medicine · UCLA

    Summary

    BACKGROUND: Islatravir once monthly (qm), a nucleoside reverse transcriptase translocation inhibitor with a long half-life, was evaluated for safety and tolerability in cisgender men and transgender women who have sex with men and are at increased likelihood of HIV-1 exposure.METHODS: IMPOWER-24 (NCT04652700) was a double-blind, Phase 3 study. Participants were randomized 2:1 to islatravir 60 mg oral qm or emtricitabine (FTC; 200 mg) coformulated with either tenofovir disoproxil (245 mg) or tenofovir alafenamide (TAF; 25 mg) once daily (qd). After ∼9 months, blinded islatravir was discontinued due to lymphocyte reductions; participants were offered open-label FTC/tenofovir disoproxil or FTC/TAF qd for 20 months.RESULTS: 494 participants were enrolled (328 islatravir; 166 comparator): 91.5% were cisgender men, 41.7% were White, and median age was 27 years. Mean blinded dosing duration was 4.7 months (islatravir) versus 4.3 months (comparator). 211 participants (64.3%) in the islatravir group and 128 (77.1%) in the comparator group had ≥1 adverse event (AE). Most AEs were mild or moderate, with one AE leading to product discontinuation (islatravir; gastroesophageal reflux). Serious AEs occurred in <2%; none were related to study product. Change in total lymphocytes in the islatravir group at Month 3 was -7.4%; a trend toward recovery was observed after islatravir was stopped. Mean total lymphocytes remained within normal range. No HIV-1 infections occurred in either group during the double-blind phase.CONCLUSION: Islatravir qm was generally well-tolerated; decreases in total lymphocytes were observed with islatravir. Original primary efficacy objectives were not assessed due to early study stoppage.
    RLDr. Raphael J. Landovitz
    Leading Voice

    Dr. Raphael J. Landovitz

    Infectious Disease · HIV & AIDS Medicine
    University of California, Los Angeles
    raphaell
    Los Angeles, CA, USA